相关实验视频

Updated: Jun 8, 2025

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

到BE或到PE:主要编辑为基于表位组编辑的免疫治疗提供了更多选择

S M Yin¹, D L Li¹

¹Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

|November 8, 2024

概括

使用基编辑 (BE) 和原始编辑 (PE) 进行皮质编辑,成功地在造血干细胞中修改了CD123. 这一进步为治疗急性髓性白血病的CAR-T疗法提供了新的策略.

科学领域:

基因编辑技术基因编辑技术
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

造血干细胞在治疗过程中容易受到免疫媒介的根除.
急性髓性白血病 (AML) 是一种血液和骨髓的癌症.
化学抗原受体 (CAR) -T细胞疗法是癌症的新兴免疫疗法.

研究的目的:

为了研究表皮图编辑在保护造血干细胞的有效性.
评估基编辑 (BE) 和主要编辑 (PE) 用于修改CD123.
探索CD123表位编辑细胞在AML的CAR-T治疗中的潜力.

主要方法:

应用基础编辑 (BE) 和主要编辑 (PE) 技术.
在造血干细胞中对CD123表位的有针对性的改变.
在体外和/或体内模型用于评估治疗潜力.

主要成果:

通过使用BE和PE,在造血干细胞中成功修改了CD123表位.
表位组编辑作为保护细胞免受免疫治疗的可行策略的演示.
对抗AML的CAR-T疗法增强疗效的潜力.

结论:

皮层编辑是一种可行的方法,可以提高CAR-T细胞治疗的安全性.
血液造血干细胞中的CD123表位编辑显示出AML治疗的前景.
BE和PE提供精确的工具来设计细胞免疫疗法.

更多相关视频

Gene Editing of Primary Rhesus Macaque B Cells

Gene Editing of Primary Rhesus Macaque B Cells

Published on: February 10, 2023

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.